Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Isolation of other micro‐organisms from the respiratory tract: number of positive cultures per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects of antibiotics: participants experiencing cough · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
It is very uncertain whether inhaled tobramycin (TNS) changes adverse effects of antibiotics: participants experiencing cough compared with placebo (very low certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Survival · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Antibiotic resistance · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · children and young adults with CF
1 finding from 1 review
Lung function: FEV1 mL (percentage change from baseline) · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FEV1mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
FEV1 % predicted · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
FVC · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FVC mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
Lung function: FEF25‐75 mL/s (percentage change from baseline) · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FEF25-75 mL/s (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
Need for additional IV or oral antibiotics · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to next pulmonary exacerbation · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
Adverse events (moderate) · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
It is very uncertain whether summary of findings: Inhaled antibiotics plus IV antibiotics changes adverse events moderate adverse events experienced during and after… compared with IV antibiotics only (very low certainty).
1 finding from 1 review